Clinical Trial Update: Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) [Phase 3]

View source ↗

Summary

Phase 3 INDIGO study of vorasidenib (AG-881) in participants with residual or recurrent IDH-mutant low-grade glioma; results were posted in 2023 while the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma

Drugs mentioned

• Vorasidenib (vorasidenib)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Grade 2 Glioma, Residual Glioma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-11-24